Member Info for Top.trader

Brilliant rns today, everything they have scheduled sounds like realistic time frames. Hiring local is going to help us with government and obviously local relations. All sounds really positive and looking forward to further updates.

I’ve got it that 10 days self isolation is complete on the 11th? Is this the consensus?

I think they still require a trained operative for reading but that’s just what I concluded from the rns. It did say results are produced in 2 seconds so it may be fully automated however, if that was the case then they would not be reducing human error they would be eliminating it, so I’m assuming they do still need to be checked by a person.

Previous magnifeye rns below, no wonder they managed to get someone on board quickly

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations. The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.



MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets. MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing. It can be used as a standalone smartphone application or incorporated into third party web or native software applications.



The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:



· Improved accuracy of reading - avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results

· Fast response - provides lateral flow test results in under 2 seconds.

· Reduced risk of fraud - identifying tests that have been tampered with

· Automated provision of validated test results - securely linking to electronic health records

· Faster generation of epidemiological insights - using Big Data analytics with the capacity to analyse the data across very large populations

· Improved security - encrypted and securely held data transfer and storage with links to healthcare providers and public health officials

· Flexible - available in iOS, Android or web app formats, as an API or SDK (software development kit)

The original magnifeye rns explains it but in brief the lateral flow tests are prone to human error when reading and magnifeye uses AI to reduce human error leading to less false positive/negative results. Cracking news as usual they may not be making money at the moment but this is a step in the right direction, when this company starts making profits the potential is huge.

Just posted a very similar question ponty, I’m wondering if it’s due to dilution with more warrants and shares being issued but don’t know the figures off the top of my head so was after some confirmation from the resident mathematicians

Was lucky enough to get in at 80p before the all time high in early jan when btc hit 42k and have been topping up since at 110p 108p and 84p.

Would you agree that the reason we are not back at ATH is because of the share dilution from the warrants? I still think this will go Further today but can’t think of any other reason that we are not back at the top. Hopefully America will drag us up a bit.

Good luck, hopefully we will see 50k btc by the end of the week with more investors piling into Argo

That’s interesting information, hopefully the product can carry it’s self the idea is brilliant but finding the right people to promote and move it forward obviously is key.

Maybe the promotional background is more geared towards US markets they do like a flashy sales pitch lol.

Martin Gouldstone was chief business officer at benevolent AI a pharma with focus on AI also has 30 years experience in pharmaceuticals and has been high up at several others. Sounds like a decent track record to me.

Hina Zaman has led change initiatives across the nhs, if she can get more trusts on bored and introduce our products to them then what is not to like?

If they are good salespeople then that is a bonus. What makes you think they are bad appointments?

I am talking about the news that phase 1 was successful being spread in medical circles. So that the opinion that monoclonal antibodies can only be administered via iv gradually changes to their might be another way for these to be introduced to patients and it doesn’t involve hospital or great expense.

Saw this on sng board but it struck me when faucci mentions monoclonal antibodies require hospital treatment and an IV treatment.

This product and initial trial results need advertising to medical professionals, we don’t seem to be getting the message through to any media currently that this is such a breakthrough. Disappointing because it answers all the issues that faucci has with mabs...

12 minutes onwards for the interview

https://youtu.be/HStAQYRreIc

Price being kept down in anticipation of a takeover bid? We know the mms have messed about with this sp before

Where did you hear about this share shin falls? I’m surprised this board isn’t a bit busier with the regular news flow

RNS sounds great, another clever use of AI from
Sensyne. Seeing it all the time on the news that ICUs are above capacity and staff are struggling to allocate beds and ventilators this takes the strain off the staff and hopefully helps the right decisions to be made. The road to £2 continues.

We have 359 million shares in issue, riot has 115 million

If the placing for small investors has filled so quickly, it suggests there’s good support and that (hopefully) the institutional investors will feel the same and be queuing up for their piece of the action.

Additionally if the share price drops and the placing for small investors was over subscribed a lot of them will still be trying to get in tomorrow. This should start us on the road back to 60p and further. With stage one of the mine potentially fully funded after the institution placing the risks for investors are massively reduced which I’m sure will soon be reflected in the share price.

There are short term potential negatives to this placing but anyone who is forward thinking will realise that a drop in share price is nothing but a good opportunity to buy.

Looking forward to open price over there. Wonder if U.K. mms will keep this down much longer.

Hopefully get to £2 today then break £2.50 on release of the further data assuming it’s as good as what’s been released this morning, which it should be!

Good day ahead

The opening price tomorrow will certainly be interesting considering the late afternoon movement. I thought it was an odd time for an rns but one benefit to it could potentially be that if the price does rise heavily on open we will show as top risers which attracts further interest. I thought 50p this morning looked cheap!

Yes another step in the right direction looks like we remain on track for 2023 production. The interview from sekker at the end did suggest to me that there might be some share dilution or placing possibly for the final bit of funding but it should be negligible when considering the gains to be made from reaching production stage.